title: Nonadjunctive Use of Continuous Glucose Monitoring for Diabetes Treatment Decisions.
abstract: While self-monitoring of blood glucose (SMBG) is the current standard used by people with diabetes to manage glucose levels, recent improvements in accuracy of continuous glucose monitoring (CGM) technology are making it very likely that diabetes-related treatment decisions will soon be made based on CGM values alone. Nonadjunctive use of CGM will lead to a paradigm shift in how patients manage their glucose levels and will require substantial changes in how care providers educate their patients, monitor their progress, and provide feedback to help them manage their diabetes. The approval to use CGM nonadjunctively is also a critical step in the pathway toward FDA approval of an artificial pancreas system, which is further expected to transform diabetes care for people with type 1 diabetes. In this article, we discuss how nonadjunctive CGM is expected to soon replace routine SMBG and how this new usage scenario is expected to transform health outcomes and patient care.
authors.affiliation: Department of Medicine, Harold Schnitzer Diabetes Health Center, Oregon Health & Science University, Portland, OR, USA castleje@ohsu.edu.
authors.forename: Jessica R
authors.initials: JR
authors.lastname: Castle
authors.affiliation: Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.
authors.forename: Peter G
authors.initials: PG
authors.lastname: Jacobs
mesh_terms: D001786:Blood Glucose / Q000032:analysis*; D015190:Blood Glucose Self-Monitoring / Q000379:methods* / Q000639:trends*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood*; D006801:Humans
chemical_list: D001786:Blood Glucose
keywords: artificial pancreas; continuous glucose monitoring; type 1 diabetes